Number of serious adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
It is very uncertain whether anti‐TNF discontinuation changes number of serious adverse events compared with anti‐TNF continuation (very low certainty).
1 finding from 1 review
Number of serious adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
It is very uncertain whether anti‐TNF disease activity–guided dose tapering changes number of serious adverse events compared with anti‐TNF continuation (very low certainty).
1 finding from 1 review
Number of serious adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
Anti‐TNF dose reduction showed no clear difference in number of serious adverse events compared with anti‐TNF continuation (low certainty).
1 finding from 1 review
Number of serious adverse events · patients with osteoarthritis
Chondroitin probably leads to lower number of serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Number of serious adverse events · patients with axSpA (AS and nr‐axSpA)
COX‐2 NSAIDs showed no clear difference in number of serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.92 [0.14, 6.21]
669 participants
Moderate
Number of serious adverse events · patients with axSpA (AS and nr‐axSpA)
Traditional NSAIDs showed no clear difference in number of serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
RR 1.69 [0.36, 7.97]
671 participants
Moderate
Number of participants experiencing any serious adverse events · patients with osteoarthritis
It is very uncertain whether celecoxib changes number experiencing any serious adverse events compared with tNSAIDs (very low certainty).
1 finding from 1 review
Number of participants experiencing any serious adverse events · patients with osteoarthritis
It is very uncertain whether celecoxib changes number experiencing any serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Total number of serious adverse events not measured · patients with osteoarthritis
The review found no eligible studies for this question.
1 finding from 1 review
Serious adverse events: number experiencing 24 weeks · Patients with osteoarthritis of the knee or hip
Paracetamol showed no clear difference in serious adverse events: number experiencing 24 weeks compared with placebo (moderate certainty).
1 finding from 1 review
SAEs · psoriatic arthritis
Methotrexate showed no clear difference in serious adverse events (SAEs) assessed by number of events compared with placebo (low certainty).
1 finding from 1 review
Number of participants experiencing any serious adverse events · patients with osteoarthritis
1 finding from 1 review
Number of participants experiencing any serious adverse events · patients with osteoarthritis
The review found no eligible studies for this question.
1 finding from 1 review
Number of participants experiencing any serious adverse events · patients with osteoarthritis
It is very uncertain whether tramadol alone changes number of participants experiencing any serious adverse events compared with NSAIDs (very low certainty).
1 finding from 1 review
Number of participants experiencing any serious adverse events · patients with osteoarthritis
It is very uncertain whether tramadol alone changes number of participants experiencing any serious adverse events compared with other opioids (very low certainty).
1 finding from 1 review
Number of participants experiencing any serious adverse events · patients with osteoarthritis
1 finding from 1 review
Number of participants experiencing any serious adverse events · patients with osteoarthritis
The review found no eligible studies for this question.
1 finding from 1 review
Number of participants experiencing any serious adverse events · Patients with osteoarthritis of the knee or hip
Tramadol alone may leads to higher number of participants experiencing any serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Number of participants experiencing any serious adverse events · patients with osteoarthritis of the ankle
1 finding from 1 review
Serious adverse events (leflunomide) assessed by number of events · psoriatic arthritis
1 finding from 1 review